Totaligent, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Totaligent, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.2K | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $444.5K | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $731.7K | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $19.5K | Oct 29, 2024 |
| FY2015 | Jun 30, 2015 | $4.74M | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $5.81M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $5.31M | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | $4.4K | May 1, 2013 |
| FY2013 | Jun 30, 2012 | $4.17M | Apr 30, 2014 |
| FY2012 | Jan 31, 2012 | $1.1K | May 1, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.2K | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $43.1K | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $250.3K | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($27.4K) | Oct 29, 2024 |
| FY2015 | Jun 30, 2015 | $1.32M | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $2.75M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $2.30M | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | $4.4K | May 1, 2013 |
| FY2013 | Jun 30, 2012 | $1.46M | Apr 30, 2014 |
| FY2012 | Jan 31, 2012 | $1.1K | May 1, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($600.0K) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($947.2K) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($402.2K) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($592.1K) | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | ($516.2K) | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | ($18.5K) | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | ($1.02M) | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | ($866.7K) | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $262.8K | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | ($1.10M) | May 1, 2013 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($455.0K) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($884.7K) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($354.0K) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($551.6K) | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | ($511.6K) | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | ($10.7K) | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | ($1.60M) | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | ($952.7K) | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $126.1K | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | ($975.3K) | May 1, 2013 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jun 30, 2015 | $815.8K | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $557.4K | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $472.2K | Oct 14, 2014 |
| FY2013 | Jun 30, 2012 | $199.1K | Apr 30, 2014 |
| FY2011 | Jan 31, 2012 | $0 | May 15, 2012 |
| FY2011 | Jan 31, 2011 | $18.8K | May 15, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Jan 31, 2013 | $979.7K | May 1, 2013 |
| FY2012 | Jan 31, 2012 | $572.9K | May 1, 2013 |
| FY2011 | Jan 31, 2011 | $2.42M | May 15, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($265.0K) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($212.5K) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($29.5K) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($175.5K) | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | ($96.3K) | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | ($10.1K) | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | ($2.79M) | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $4.81M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | ($2.86M) | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | ($986.5K) | May 1, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $24.1K | Oct 29, 2024 |
| FY2015 | Jun 30, 2015 | $54.5K | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $127.3K | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $32.1K | Oct 14, 2014 |
| FY2013 | Jun 30, 2012 | $84.5K | Apr 30, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $206.5K | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $222.9K | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $486.8K | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $149.1K | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | $317.2K | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $31.6K | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | $33.36M | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $42.25M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $39.24M | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | $204.3K | May 1, 2013 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | $1.96M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | $1.40M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | $910.1K | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | $636.6K | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | $28.93M | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $35.70M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $31.58M | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | $594.6K | May 1, 2013 |
| FY2013 | Jun 30, 2012 | $32.21M | Apr 30, 2014 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.16M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($1.74M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2023 | ($910.0K) | Apr 3, 2026 |
| FY2024 | Dec 31, 2022 | ($761.1K) | Apr 9, 2025 |
| FY2023 | Dec 31, 2021 | ($169.0K) | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | ($319.4K) | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $31.6K | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | $4.43M | Sep 17, 2015 |
| FY2016 | Dec 31, 2014 | ($91.8K) | Mar 28, 2017 |
| FY2015 | Jun 30, 2014 | $6.56M | Sep 17, 2015 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Jun 30, 2015 | $58.1K | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | $71.2K | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | $69.1K | Oct 14, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.56M) | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | ($1.81M) | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | ($860.1K) | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | ($458.0K) | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | ($626.5K) | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | ($110.3K) | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | ($8.64M) | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | ($7.62M) | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | ($6.75M) | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | ($10.69M) | May 1, 2013 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $15.6K | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | $452 | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | $8.08M | Sep 17, 2015 |
| FY2016 | Dec 31, 2014 | $518 | Mar 28, 2017 |
| FY2015 | Jun 30, 2014 | $10.73M | Sep 17, 2015 |
| FY2015 | Jun 30, 2013 | $7.14M | Sep 17, 2015 |
| FY2012 | Jan 31, 2013 | $13.0K | May 1, 2013 |
| FY2014 | Jun 30, 2012 | $5.62M | Oct 14, 2014 |
| FY2012 | Jan 31, 2012 | $35.8K | May 1, 2013 |
| FY2013 | Jun 30, 2011 | $2.85M | Apr 30, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Jun 30, 2014 | 0 | Oct 14, 2014 |
| FY2014 | Jun 30, 2013 | 0 | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | 0 | May 1, 2013 |
| FY2013 | Jun 30, 2012 | 0 | Apr 30, 2014 |
| FY2012 | Jan 31, 2012 | 0 | May 1, 2013 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 9, 2025 |
| FY2014 | Jun 30, 2013 | 0 | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | 0 | May 1, 2013 |
| FY2013 | Jun 30, 2012 | 0 | Apr 30, 2014 |
| FY2012 | Jan 31, 2012 | 0 | May 1, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 213.60M | Apr 3, 2026 |
| FY2025 | Dec 31, 2024 | 172.91M | Apr 3, 2026 |
| FY2024 | Dec 31, 2023 | 172.91M | Apr 9, 2025 |
| FY2023 | Dec 31, 2022 | 94.76M | Oct 29, 2024 |
| FY2016 | Dec 31, 2016 | 10.75M | Mar 28, 2017 |
| FY2016 | Dec 31, 2015 | 1.66M | Mar 28, 2017 |
| FY2015 | Jun 30, 2015 | 7.67M | Sep 17, 2015 |
| FY2015 | Jun 30, 2014 | 7.67M | Sep 17, 2015 |
| FY2014 | Jun 30, 2013 | 9.96M | Oct 14, 2014 |
| FY2012 | Jan 31, 2013 | 207.66M | May 1, 2013 |